作者: Casabella, Andrea ; Clapasson, Andrea ; Gariazzo, Lodovica ; Murgioni, Franca ; Carmisciano, Luca ; Gasparini, Giulia ; Parodi, Aurora ; Cozzani, Emanuele ; Molfetta, Luigi

AbstractBackgroundUltraviolet (UV) radiation has numerous beneficial effects on human health, including stimulating vitamin D and serotonin production and immuno‐regulatory activities. Conversely, UV radiation is also classified as a group one carcinogen by the International Agency for Research on Cancer.PurposeTo investigated the effects of UV radiation avoidance in melanoma patients in terms of vitamin D levels but also of bone mineral density and trabecular bone microarchitecture.MethodsWe conducted an observational study investigating the effects of UV radiation avoidance in 31 melanoma patients in terms of vitamin D levels but also of bone mineral density and trabecular bone microarchitecture by using dual‐energy X‐ray absorptiometry scan. Data were compared with two control groups of healthy subjects, who were chronically exposed or not exposed to UV radiation during their lifetime.ResultsMelanoma patients had on average slightly lower levels of vitamin D, without reaching statistical significance (P = .135). No significant difference was found across the three groups on T‐scores of femoral neck (P = .544), of total hip (P = .617) and of lumbar spineP = .155). No significant difference was found on and trabecular bone score across exposure groups (P = .895).ConclusionUV radiation avoidance does not seem to significantly impact vitamin D levels nor bone health in melanoma patients. Thus, UV protective behavior is advisable for all melanoma patients.

2018-02-15·Cancer Research1区 · 医学

miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma

1区 · 医学

Article

作者: Teixidó, Joaquin ; Koetz-Ploch, Lisa ; Alonso, Lola ; Benito-Jardón, Lucía ; Hernando, Eva ; Díaz-Martínez, Marta

AbstractMelanoma treatment with the BRAF V600E inhibitor vemurafenib provides therapeutic benefits but the common emergence of drug resistance remains a challenge. We generated A375 melanoma cells resistant to vemurafenib with the goal of investigating changes in miRNA expression patterns that might contribute to resistance. Increased expression of miR-204-5p and miR-211-5p occurring in vemurafenib-resistant cells was determined to impact vemurafenib response. Their expression was rapidly affected by vemurafenib treatment through RNA stabilization. Similar effects were elicited by MEK and ERK inhibitors but not AKT or Rac inhibitors. Ectopic expression of both miRNA in drug-naïve human melanoma cells was sufficient to confer vemurafenib resistance and more robust tumor growth in vivo. Conversely, silencing their expression in resistant cells inhibited cell growth. Joint overexpression of miR-204-5p and miR-211-5p durably stimulated Ras and MAPK upregulation after vemurafenib exposure. Overall, our findings show how upregulation of miR-204-5p and miR-211-5p following vemurafenib treatment enables the emergence of resistance, with potential implications for mechanism-based strategies to improve vemurafenib responses.Significance: Identification of miRNAs that enable resistance to BRAF inhibitors in melanoma suggests a mechanism-based strategy to limit resistance and improve clinical outcomes. Cancer Res; 78(4); 1017–30. ©2017 AACR.

2017-07-01·Quality of Life Research2区 · 医学

Comparison of quality of life among long-term melanoma survivors and non-melanoma controls: a cross-sectional study

2区 · 医学

Article

作者: Lazovich, DeAnn ; Blaes, Anne H ; Engelman, Leah ; Nelson, Heather H ; Strayer, Lori G ; Anderson, Kristin E ; Vogel, Rachel Isaksson

PURPOSELittle is known about specific concerns facing long-term melanoma survivors. The goal of this study was to compare quality of life (QOL) and mental health between long-term melanoma survivors and population controls.METHODSParticipants from a previously conducted case-control study of risk factors for melanoma were recruited for a cross-sectional survey. Generic QOL and emotional health were measured using the SF-36 and Hospital Anxiety and Depression Scale questionnaires. A total of 724 melanoma survivors and 660 controls participated. Most melanoma survivors had stage I disease (85.6%); mean time from diagnosis was 9.6 ± 1.0 years. Comparisons of QOL measures between melanoma survivors and controls were conducted using regression models, adjusting for potential confounders.RESULTSMelanoma survivors, compared to controls, reported statistically significant but only slightly higher physical functioning and bodily pain QOL subscale scores than controls and otherwise similar QOL as measured by the remaining six SF-36 subscale scores. Prevalence of anxiety (18.1% vs. 19.3%, adjusted OR = 1.00 (0.74, 1.36); p = 1.00) and depression (7.2% vs. 9.8%, adjusted OR = 0.74 (0.48, 1.16); p = 1.00) were similar between melanoma survivors and controls.CONCLUSIONLong-term early stage melanoma survivors report similar general QOL and mental health compared to population controls. Further research is needed to identify concerns more specific to melanoma.

100 项与 Melanoma(OncoTartis) 相关的药物交易

登录后查看更多信息